Eli Lilly and Company

Rosamund Carol Smith

Kristine Kay Kikly

Andrew Ihor Korytko

Pamela Jean Mitchell

Linda Maureen O'Bryan

Rong Wang

Julian Davies

Bryan Edward Jones

Linda O'Bryan (Nee Tobias)

Bomie Han

Jirong Lu

Donmienne Doen Mun Leung

Kalpana Mahesh Merchant

Matthew Douglas Breyer

Mahmoud Ghanem

Donmienne Doen Leung

Linda Maureen O'bryan

Linda O O'Bryan

Linda O Tobias

The present invention relates to novel variants of human glial cell-derived neurotrophic factor (GDNF) and methods for their use.

Variants of human GDNF

The present invention relates to therapeutic uses of soluble alpha-Klotho.

Therapeutic uses of soluble alpha-Klotho

Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bond density, or for the treatment of various disorders in mammalian and avian species, X17251.

Anti-myostatin antibodies

A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing hone density, or for the treatment of various disorders in mammalian and avian species.

A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.

Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.

Growing community of inventors

Greenfield, IN, United States of America

Rosamund Carol Smith